Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why IVIG, infection monitoring, and deeper bridging responses matter with myeloma immunotherapy.
Mateo Mejia Saldarriaga, MD
Advertisement
Articles by Mateo Mejia Saldarriaga, MD
Weill Cornell's Mateo Mejia Saldarriaga, MD, discusses patient preference for on-body isatuximab and how to sequence CAR T and bispecifics in myeloma.
Advertisement
Latest Updated Articles
MM Infection Risk and Bridging Therapy: Mateo Mejia Saldarriaga, MDOctober 20th 2026
- On-Body Isatuximab Eases Myeloma Care: Mateo Mejia Saldarriaga, MD
October 12th 2026
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Cranberry Supplement Tied to Greater OAB Score Reductions in Pilot Trial
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5